Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: Efficacy and incidence of hepatic veno-occlusive disease

Bone Marrow Transplantation

Volumn 30, Issue 1, 2002, Pages 23-28

  Cohen, A D ^a   Luger, S M ^a   Sickles, C ^a   Mangan, P A ^a   Porter, D L ^a   Schuster, S J ^a   Tsai, D E ^a   Nasta, S ^a   Gewirtz, A M ^a   Stadtmauer, E A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute myeloid leukemia; Gemtuzumab ozogamicin; Hepatic veno occlusive disease; Mylotarg; Stem cell transplant

Indexed keywords

BLEOMYCIN; BUSULFAN; CALICHEAMICIN; CARMUSTINE; CD33 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MALE; MONOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ACUTE DISEASE; ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; CAUSE OF DEATH; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOTOXINS; INCIDENCE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0036054270     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703602     Document Type: Article

References (33)

1. Acute myeloid leukemia
2. Management of relapsed acute myeloid leukaemia
3. Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 years
4. Expression of normal myeloid-associated antigens by acute leukemia cells
5. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
6. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
7. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation
8. Veno-occlusive disease of the liver
9. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: Current status and novel approaches
10. Veno-occlusive disease of the liver after hemopoietic cell transplantation
11. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients
12. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in efficacy without significant toxicity in a high risk population
13. Actinomycin D associated hepatic veno-occlusive disease - A report of 2 cases
14. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma
15. Hepatic venoocclusive disease caused by 6-thioguanine
16. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate
17. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
18. Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676): Relationship to hematopoietic stem cell transplantation
19. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
20. Tolerability and side-effect profile of rhIL-11
21. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy
22. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: Incidence, onset time and risk factors
23. Immunophenotypic characterization of human fetal liver hematopoietic stem cells during the midtrimester of gestation
24. Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liver
25. Expression of CD33, CD38, and HLA-DR on CD34+ human fetal liver progenitors with a high proliferative potential
26. Differential expression of surface antigens on activated endothelium
27. Antibody-targeted therapy for myeloid leukemia
28. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia
29. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias
30. Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676)
31. 1: An antitumor antibiotic that cleaves double-stranded DNA site specifically
32. Current use and future development of gemtuzumab ozogamicin
33. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer